Align Technology is a medical device company known primarily for its innovative dental products, including the Invisalign system, which offers a clear alternative to traditional metal braces for orthodontic treatment
The company focuses on transforming patients' smiles through advanced 3D computer modeling and digital scanning technologies, enabling customized treatment plans. In addition to its flagship product, Align Technology also produces a range of other tools and software that enhance dental practice efficiency and patient care, serving both orthodontists and general dentists. By combining cutting-edge technology with a commitment to improving oral health, Align Technology aims to empower patients and revolutionize the field of orthodontics.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Henry Schein (NASDAQHSIC) and the best and worst performers in the dental equipment & technology industry.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $225 million of Align’s common stock through open market repurchases, which will complete Align’s $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023, in its entirety.
Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Align's Invisalign Palatal Expander System has been approved by the Turkish Medicines and Medical Device Agency (TMMDA) and is now commercially available in Turkey. The approval is for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques).
Dental technology company Align Technology (NASDAQALGN) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4% year on year to $995.2 million. On the other hand, next quarter’s revenue guidance of $975 million was less impressive, coming in 5.5% below analysts’ estimates. Its non-GAAP profit of $2.44 per share was in line with analysts’ consensus estimates.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the fourth quarter ("Q4'24") and year ended December 31, 2024 ("2024"). Q4'24 total revenues were $995.2 million, up 1.8% sequentially and up 4.0% year-over-year. Q4'24 total revenues were favorably impacted by foreign exchange of approximately $0.8 million or 0.1% sequentially and unfavorably impacted by approximately $0.9 million or 0.1% year-over-year.(1) Q4'24 Clear Aligner revenues were $794.3 million, up 0.9% sequentially and up 1.6% year-over-year. Q4'24 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $0.7 million or 0.1% sequentially and unfavorably impacted by approximately $0.7 million or 0.1% year-over-year.(1) Q4'24 Clear Aligner volume was up 1.9% sequentially and up 6.1% year-over-year. Q4'24 Imaging Systems and CAD/CAM Services revenues were $200.9 million, up 5.2% sequentially and up 14.9% year-over-year. Q4'24 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $0.1 million or flat sequentially and unfavorably impacted by approximately $0.2 million or 0.1% year-over-year.(1) Q4'24 operating income was $144.1 million resulting in an operating margin of 14.5%. Q4'24 operating margin was favorably impacted by foreign exchange of approximately 0.1 points sequentially and unfavorably impacted by approximately 0.2 points year-over-year.(1) Q4'24 net income was $103.8 million, or $1.39 per diluted share. Q4’24 diluted net income per share was unfavorably impacted by a stronger U.S. dollar, which amounted to approximately $0.14 per diluted share due to net foreign exchange losses related to the revaluation of certain balance sheet accounts. On a non-GAAP basis, Q4'24 net income was $181.6 million, or $2.44 per diluted share. During Q4'24, we incurred a total of $37.0 million of restructuring and other charges, primarily related to post-employment benefits.
Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Patrick Mahomes, quarterback for the National Football League’s (NFL) Kansas City Chiefs, has joined the Invisalign Smile Squad as an ambassador for the brand. As part of the multi-year agreement, Patrick will share his Invisalign treatment experience with fans in a multi-channel campaign.
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and 2024 financial results on Wednesday, February 5, 2025, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.
Patient Square Capital agrees to buy Patterson Companies for $4.1 billion. Analysts predict minimal regulatory hurdles and a strong bid unlikely to face competition.
Align Technology Inc.’s third-quarter results did not show much progress towards regaining its old growth momentum, but some small signs of improvement were enough to give shares a recent boost.
Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has received CE Mark in Europe under the Medical Device Regulation (MDR 2017/745) for Align’s Invisalign® Palatal Expander System. The Invisalign Palatal Expander System has also completed registration with MHRA for the United Kingdom and overseas territories.
